Sign in
Back
Estrogen Receptor Determination Predicts Response to Tamoxifen Therapy
Book chapter

Estrogen Receptor Determination Predicts Response to Tamoxifen Therapy

J. C Allegra and M. E Lippman
Endocrine Treatment of Breast Cancer, pp.16-19
Recent Results in Cancer Research / Fortschritte der Krebsforschung / Progrès dans les recherches sur le cancer, Springer Berlin Heidelberg
DOI: https://doi.org/10.1007/978-3-642-81406-8_5

Abstract

Advanced Breast Cancer Metastatic Breast Cancer Estrogen Receptor Estrogen Receptor Status Breast Cancer
Tamoxifen (TAM, ICI 46,474) is a nonsteroidal antiestrogen of the triphenylethylene family. The clinical use of TAM was first reported in 1971 (Cole et al., 1971), and early clinical trials suggested that TAM was useful in the treatment of metastatic breast cancer (Cole et al., 1971; Ward, 1973; Cole et al., 1972). These studies yielded response rates ranging between 15% and 60% with minimal toxicity.

Metrics

2 Record Views

Details